View:
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------
FORM 8-K
---------------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): November 27, 2001
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-28150 33-0525145
(State or other (Commission File Number) (IRS Employer
jurisdiction of Identification Number)
incorporation)
10555 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (858) 658-7600
N/A
(Former name or former address, if changed since last report.)
================================================================================
This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a
Delaware corporation (the "Company"), in connection with the matters described
herein.
ITEM 5. OTHER EVENTS
On November 27, 2001, the Company announced that it intends to file a
preliminary prospectus supplement to its $200 million universal shelf
registration statement with the Securities and Exchange Commission relating to
the proposed underwritten public offering of 3,250,000 shares of its common
stock. A copy of the Company's press release announcing its intention to file a
preliminary prospectus supplement, dated November 27, 2001, is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
ITEM 7. EXHIBITS
(c) Exhibits. The following exhibits are filed herewith:
Exhibit
Number Description of Exhibit
------------ -----------------------------------------
99.1 Press Release, dated November 27, 2001.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: November 27, 2001 /s/ Paul W. Hawran
----------------- ------------------
Paul W. Hawran
Executive Vice President and
Chief Financial Officer
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
- -------- ------------------------------------------------------------
99.1 Press Release, dated November 27, 2001.
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact at Neurocrine Biosciences
Elizabeth Foster or Paul Hawran
(858) 658-7600
NEUROCRINE BIOSCIENCES TO FILE PRELIMINARY PROSPECTUS
SUPPLEMENT FOR 3,250,000 SHARE PUBLIC OFFERING
San Diego, CA, November 27, 2001-Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
today announced that it intends to file a preliminary prospectus supplement to
its $200 million universal shelf registration statement with the Securities and
Exchange Commission relating to the proposed underwritten public offering of
3,250,000 shares of its common stock. The company also proposes to grant an
option to the underwriters to purchase up to 487,500 shares of common stock
solely to cover over-allotments. All of the shares are being sold by Neurocrine
Biosciences.
The joint bookrunning managers for the offering announced today are Deutsche
Banc Alex. Brown and Credit Suisse First Boston Corporation. Co-managers of this
offering are CIBC World Markets Corp., Lehman Brothers Inc., and UBS Warburg
LLC.
A preliminary prospectus supplement relating to the shares referenced above is
expected to be filed with the Securities and Exchange Commission tomorrow. These
securities may not be sold nor may offers to buy be accepted prior to the time
that the prospectus supplement is final. This communication shall not constitute
an offer to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any state in which such offer, solicitation or sale
would be unlawful prior to registration of qualification under the securities
laws of any such state.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, malignant brain tumors and peripheral
cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating
disorders, pain, stroke, and certain female health disorders.
Copies of the preliminary prospectus supplement may be obtained from the
Prospectus Departments at Deutsche Banc Alex. Brown, One South Street,
Baltimore, MD 21202, (410) 895-2070, Credit Suisse First Boston Corporation,
Eleven Madison Avenue, New York, NY 10010, (212) 325-2000 or from the offices of
any of the managing underwriters identified above.
###